Jade Biosciences Inc. (JBIO)
NASDAQ (CM) NASDAQ (CM) Primary 
Jade Biosciences: Duration Is The Real Product
Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA reduction with a favorable safety profile; Phase 2 JUNIPER trial interim data expected in 2027 will be pivotal. JBIO's pipeline includes JADE201 (anti-BAFF-R antibody) and JADE301 (IFN-beta inhibitor), both engineered for extended-interval dosing to differentiate in validated autoimmune markets.
Jade Biosciences' JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
Jade Biosciences NASDAQ: JBIO said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company's plan to advance the antibody into patient studies for IgA nephropathy.
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect?
The mean of analysts' price targets for Jade Biosciences, Inc. (JBIO) points to a 65% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock
Jade Biosciences, Inc. (JBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know
The mean of analysts' price targets for Jade Biosciences, Inc. (JBIO) points to a 52.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
